Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trial - PubMed
6 hours ago
- #SARS-CoV-2 variants
- #self-amplifying mRNA vaccine
- #antibody durability
- Self-amplifying mRNA (sa-mRNA) vaccines, such as ARCT-154, prolong antigen production and enhance durability of antibody responses.
- In a Phase III trial, ARCT-154 induced unique antibody profiles, including sustained FcγRIIIA-binding antibodies, compared to BNT162b2.
- ARCT-154 vaccination led to enhanced natural killer (NK) cell activation against both wild-type and BA.5 variant SARS-CoV-2 Spike proteins.
- The prolonged antigen expression from sa-mRNA vaccines promotes activating immune phenotypes with broad antigenic coverage.
- Participants received three doses of mRNA vaccines prior to boosting with ARCT-154 or BNT162b2, analyzed through systems serology.